Soluble Il-17Rc Variant and Uses Thereof
The present invention relates to a new soluble IL-17RC variant and its therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders or neurological diseases.
1 - 16 . (canceled)
17 . An isolated polypeptide comprising:
a) a soluble IL-17RC variant polypeptide comprising SEQ ID NO: 1;
b) a soluble IL-17RC variant polypeptide comprising SEQ ID NO: 1 fused to: a carrier molecule; peptide; a polypeptide; or a protein that promotes crossing of the blood brain barrier; or
c) a soluble PEGylated IL-17RC variant polypeptide comprising SEQ ID NO: 1.
18 . The isolated polypeptide according to claim 17 , wherein said polypeptide is a soluble IL-17RC variant polypeptide comprising SEQ ID NO: 1 that is fused to a carrier molecule; a peptide; a polypeptide; or a protein that promotes the crossing of the blood brain barrier.
19 . The isolated polypeptide according to claim 17 , wherein said polypeptide is a soluble PEGylated IL-17RC variant polypeptide.
20 . The isolated polypeptide according to claim 17 , wherein said soluble IL-17RC variant polypeptide comprising SEQ ID NO: 1 is fused to a polypeptide and said polypeptide is an immunoglobulin (Ig) molecule or the constant region of an immunoglobulin molecule.
21 . The isolated polypeptide according to claim 17 , wherein said soluble IL-17RC variant polypeptide comprises SEQ ID NO: 1.
22 . An isolated nucleic acid molecule encoding:
a) a soluble IL-7RC variant polypeptide comprising SEQ ID NO: 1; or
b) a soluble IL-17RC variant polypeptide comprising SEQ ID NO: 1 fused to: a carrier molecule; peptide; a polypeptide; or a protein that promotes crossing of the blood brain barrier.
23 . The isolated nucleic acid molecule of claim 22 , wherein said nucleic acid molecule encodes a soluble IL-17RC variant polypeptide comprising SEQ ID NO: 1 that is fused to a carrier molecule; a peptide; a polypeptide; or a protein that promotes the crossing of the blood brain barrier.
24 . The isolated nucleic acid molecule according to claim 22 , wherein said nucleic acid molecule encodes a soluble PEGylated IL-17RC variant polypeptide comprising SEQ ID NO: 1.
25 . The isolated nucleic acid molecule according to claim 22 , wherein said nucleic acid molecule comprises SEQ ID NO: 2.
26 . An expression vector comprising the nucleic acid molecule according to claim 22 .
27 . A host cell transfected with a vector according to claim 26 .
28 . A process for the production of a soluble IL-17RC variant proteins, comprising the step of culturing a host cell according to claim 27 under conditions that allow for the expression of said soluble IL-17RC variant proteins.
29 . The process according to claim 28 , further comprising isolating the expressed IL-17RC variant proteins from the host cell.
30 . The process according to claim 28 , further comprising purifying the expressed IL-17RC variant proteins.
31 . The process according to claim 30 , further comprising the step of formulating the purified IL-17RC variant proteins into a pharmaceutical composition.
32 . An isolated antibody specifically binding with a soluble IL-17RC variant according to claim 17 .
33 . The isolated antibody according to claim 32 , wherein said antibody is a monoclonal antibody, a polyclonal antibody, a humanized antibody or a human antibody.
34 . A method of treating an autoimmune disease, inflammatory disorder or neurological disease comprising the administration of a composition comprising a polypeptide according to claim 17 to an individual having an autoimmune disease, inflammatory disorder or neurological disease in an amount effective to treat said disease or disorder.
35 . A pharmaceutical composition comprising a soluble IL-17RC according to claim 17 and one or more pharmaceutically acceptable excipients.